Scinai Immunotherapeutics
(NASDAQ) SCNI
Scinai Immunotherapeutics Financials at a Glance
Market Cap
$603,600
Revenue (TTM)
$1.26M
Net Income (TTM)
$7.97M
EPS (TTM)
$-12.27
P/E Ratio
-0.06
Dividend
$0.00
Beta (Volatility)
0.94 (Low)
Dividend
$0.00
Beta (Volatility)
0.94 (Low)
Price
$0.70
Volume
8,123
Open
$0.74
Price
$0.70
Volume
8,123
Open
$0.74
Previous Close
$0.71
Daily Range
$0.69 - $0.74
52-Week Range
$0.61 - $6.18
Dividend
$0.00
Beta (Volatility)
0.94 (Low)
Price
$0.70
Volume
8,123
Open
$0.74
Previous Close
$0.71
Daily Range
$0.69 - $0.74
52-Week Range
$0.61 - $6.18
SCNI News
SCNI: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Scinai Immunotherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
31
CEO
Amir Reichman, MBA
Website
www.scinai.comHeadquarters
Jerusalem, IL
SCNI Financials
Key Financial Metrics (TTM)
Gross Margin
-1%
Operating Margin
-6%
Net Income Margin
-6%
Return on Equity
138%
Return on Capital
-72%
Return on Assets
-67%
Earnings Yield
-16.67%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$603.60K
Shares Outstanding
853.00K
Volume
8.12K
Short Interest
0.00%
Avg. Volume
46.00K
Financials (TTM)
Gross Profit
$580.00K
Operating Income
$8.64M
EBITDA
$6.99M
Operating Cash Flow
$6.33M
Capital Expenditure
$12.00K
Free Cash Flow
$6.35M
Cash & ST Invst.
$1.96M
Total Debt
$2.09M
Scinai Immunotherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$277.29K
+65.1%
Gross Profit
$0.00
+100.0%
Gross Margin
0.00%
N/A
Market Cap
$603.60K
N/A
Market Cap/Employee
$19.47K
N/A
Employees
31
N/A
Net Income
$2.12M
-120.3%
EBITDA
$963.49K
-107.5%
Quarterly Fundamentals
Net Cash
$1.37M
+92.3%
Accounts Receivable
$139.00K
+16.8%
Inventory
$0.00
N/A
Long Term Debt
$1.86M
-90.9%
Short Term Debt
$497.00K
-31.7%
Return on Assets
-67.28%
N/A
Return on Invested Capital
-71.91%
N/A
Free Cash Flow
$1.29M
+26.7%
Operating Cash Flow
$1.29M
+26.8%